Nanobiotix S.A. (5NR.F)

6,14 -0,03 (-0,49%) Ab 09:59AM CEST. Markt geöffnet.

Nanobiotix S.A.

60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 102

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Laurent Levy Ph.D.	Co-Founder, President of the Executive Board & CEO	713,87k	N/A	1973
Mr. Bart Van Rhijn	CFO & Member of Executive Board	628,49k	N/A	1973
Ms. Anne-Juliette Hermant M.A.	Chief People Officer & Member of Executive Board	354,9k	N/A	1974
Dr. Louis Kayitalire M.D.	Chief Medical Officer	500,8k	N/A	1958
Mr. Earl J. Bergey Ph.d.	Co-Founder	N/A	N/A	1955
Mr. Craig West CFA	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Brandon Owens	VP of Strategic Marketing & Corporate Communication	N/A	N/A	N/A
Mr. Patrick Tricoli M.B.A., Pharm.D.	Global Head of Business Development	N/A	N/A	N/A
Ms. Margaret Galluzzi	VP & Global Head of Clinical Operations	N/A	N/A	N/A
Mr. Ventzislav Vassilev M.D.	VP & Global Head of Safety Vigilance	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Corporate Governance

Nanobiotix S.A.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 7, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.